NHS National Framework for Transition products (Nilotinib and Ticagrelor)

NHS ENGLAND

There is 1 contract in this contracting process.

Summary of the contracting process

NHS England is currently in the planning stage for a procurement process to establish the NHS National Framework for Transition products, including Nilotinib and Ticagrelor. This initiative, aimed at the pharmaceutical products industry, involves a framework agreement commencing on 1st September 2025 and is set to run until 31st January 2027, with potential extensions up to 2029. Based in Leeds, United Kingdom, NHS England is seeking supplier engagement by 25th April 2025, indicating the preparation for a detailed tender phase. The total value of the contract may amount to approximately £34.85 million gross. Key compliance with UK Public Contracts Regulations is ensured, offering a structured procurement method.

This tender presents significant growth opportunities for businesses involved in the production and supply of pharmaceutical products, particularly those specialising in cardiovascular medication. Small and medium-sized enterprises (SMEs) are especially encouraged to participate, as the framework agreement has been structured to accommodate the capabilities of smaller suppliers. Companies that can provide Nilotinib and Ticagrelor efficiently and meet the demanding standards of NHS England will find this an advantageous contract, offering substantial business growth and a stable supply relationship with a prominent public authority.

This is an AI-generated summary 🚀

How useful is this summary?

Planning

NHS National Framework for Transition products (Nilotinib and Ticagrelor)

NHS ENGLAND

Contract Timeline

Publication Date

9th April 2025 11:44:57 AM

Planning Deadline

25th April 2025 22:59:59 PM Expired
Contract Summary

Project title: NHS National Framework for Transition products (Nilotinib and Ticagrelor) commencing 1st September 2025 Offer reference number: CM/TNS/24/5721 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum of 24 months. Potential periods of call-offs under the framework agreement: CM/TNS/24/5721/01 - Nilotinib and Ticagrelor Lot 1 DCE/DNW/DNE: 01/09/2025 to 31/01/2027 (17 months) Lot 2 DLN/DLS/DSW: 01/09/2025 to 31/01/2027 (17 months) Published By: Medicines Procurement and Supply Chain – NHS Medicines Value & Access, NHS England
Contract Details

Open Contracting ID

ocds-h6vhtk-04ff91

Publication Source

Find a Tender Service

Procurement Stage

Planning

Procurement Method

N/A

Procurement Method Details

N/A

Procurement Category

Goods

Tender Suitability

Framework / DPS

Framework
Contract Classification

CPV Code(s)

CPV Division(s)
Awarding Authority

NHS ENGLAND

Buyer Name

Buyer Email

katie.noonan@nhs.net

Buyer Phone

Buyer Address

7-8 Wellington Place

Leeds

LS1 4AP

United Kingdom

View contract on Find a Tender Service

NHS National Framework for Transition products (Nilotinib and Ticagrelor)

NHS ENGLAND

Contract Timeline

Contract Summary

Contract Details

Contract Classification

Awarding Authority